Related Experiment Videos
Psychiatric applications of bromocriptine therapy
P A Sitland-Marken1, B G Wells, J H Froemming
1Division of Pharmacy Practice, School of Pharmacy, University of Missouri, Kansas City 64108-2792.
The Journal of Clinical Psychiatry
|February 1, 1990
Summary
Bromocriptine, a dopamine-acting drug, shows potential for treating neuroleptic malignant syndrome, cocaine withdrawal, and depression. Further research is needed to confirm its psychiatric applications and optimal use.
Area of Science:
- Psychiatry
- Neuropharmacology
Background:
- Bromocriptine, an ergot alkaloid derivative, exhibits dopamine agonist and antagonist properties.
- Its application in psychiatric disorders is supported by limited case reports and small trials with methodological issues.
Purpose of the Study:
- To critically review existing literature on bromocriptine in psychiatric illnesses.
- To analyze efficacy, mechanisms, dosing, side effects, and predictors of response.
Main Methods:
- Literature review of case reports and small clinical trials.
- Critical analysis of study methodologies and reported outcomes.
Main Results:
- Preliminary data suggest potential efficacy in neuroleptic malignant syndrome, cocaine withdrawal, and depression.
- Apparent lack of efficacy in tardive dyskinesia, mania, and schizophrenia may relate to excessive dosing and postsynaptic effects.
Conclusions:
- Bromocriptine shows promise for specific psychiatric conditions, warranting further investigation.
- Extensive clinical trials are necessary to establish its definitive role and optimal therapeutic strategies in psychiatry.